Sodium aurothiomalate


Generic Medicine Info
Contraindications
Exfoliative dermatitis, SLE, necrotising enterocolitis, pulmonary fibrosis. History of haematological disorders, toxicity to heavy metals. Severely debilitated patients. Severe renal or hepatic impairment. Concomitant use w/ antimalarials, immunosuppressive agents, penicillamine or phenylbutazone.
Special Precautions
Patient w/ DM, heart failure, marked HTN, compromised cerebral or CV circulation. History of urticaria, eczema or colitis. Mild to moderate renal or hepatic impairment. Childn. Pregnancy and lactation. Monitoring Parameters Perform CBC w/ differential, platelet count, urinalysis for protein and LFT prior to initiation of therapy. Skin and oral mucosa inspection.
Adverse Reactions
Pruritus, stomatitis, erythema multiforme, urticaria, eczema, seborrhoeic dermatitis, lichenoid eruptions, alopecia, exfoliative dermatitis, glossitis, pharyngitis, vaginitis, photosensitivity reactions, chrysiasis, eosinophilia, thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia, proteinuria, haematuria, nephrosis, pulmonary fibrosis, dyspnoea, toxic hepatitis, cholestatic jaundice, peripheral neuritis, encephalitis, psychoses, fever, weakness, flushing, palpitations, syncope. Rarely, iritis, corneal ulcers, golds deposit in the eye.
Potentially Fatal: Rarely, ulcerative colitis.
Drug Interactions
May increase risk of aspirin-induced liver damage. Increased risk of severe anaphylactoid reaction when used w/ ACE inhibitors.
ATC Classification
M01CB01 - sodium aurothiomalate ; Belongs to the class of gold preparations of antirheumatic agents.
Disclaimer: This information is independently developed by CIMS based on sodium aurothiomalate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in